- Net sales amounted to TSEK 198 (TSEK 132).
- Earnings before interest and taxes (EBIT) amounted to MSEK -5,2 (MSEK 6,2).
-
Earnings per share after dilution at
SEK -0,07 (SEK 0,09 ). - Cash flow from operating activities amounted to TSEK -5 114 (TSEK -6 214).
- Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
- Equity ratio was 77 % (86 %).
- Net sales amounted to TSEK 904 (TSEK 472).
- Earnings before interest and taxes (EBIT) amounted to MSEK -16,4 (MSEK 3,98).
-
Earnings per share after dilution at
SEK -0,23 (SEK 0,06 ). - Cash flow from operating activities amounted to MSEK -12,7 (MSEK -3,46).
- Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
- Equity ratio was 77 % (86 %).
Summary of events during third quarter
- RLS issues new shares by way of set-off, totaling TSEK 10 000.
-
An article regarding ChloraSolv is published in
Journal of Wound Care .
Summary of events after third quarteR
- New CEO
Björn Larsson startsOctober 1 . -
RLS has raised liquid assets through a new issue in
November 2022 (rights issue) of MSEK 29.4. The Swedish Medicines Agency has approved RLS' application for pressure ulcers.-
RLS visits the conference Wounds
UK inHarrogate, England .
The Interim Report Q3, 2022, is enclosed and is also available here.
Publication
This information was submitted for publication through the agency of the below contact person, at 08.00 CET on
TRADING PLACE AND CERTIFIED ADVISER:
FOR MORE INFORMATION, PLEASE CONTACT:
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25
Eva Jagenheim, CFO,
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57
ABOUT
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global
https://news.cision.com/rls-global-ab/r/rls-global-ab--publ--interim-report--q3--2022,c3671967
https://mb.cision.com/Main/12052/3671967/1692296.pdf
(c) 2022 Cision. All rights reserved., source